期刊文献+

男性腹型肥胖患者腹部脂肪面积与胰岛素抵抗的相关性分析 被引量:5

The correlation of intra-abdominal fat area with insulin resistance in male with abdominal obesity
原文传递
导出
摘要 目的:探讨男性腹型肥胖患者腹部脂肪面积与糖代谢指标的关系。方法选择21~62岁肥胖男性94例,其中腹围≥90 cm(腹型肥胖组)70例,<90 cm(均匀肥胖组)24例,登记两组患者的一般资料,测量身高、体质量、腹围、臀围,计算体质量指数(BMI);受试者空腹行口服葡萄糖耐量试验,检测血糖(0、1、2 h)及胰岛素(0、1、2 h),计算胰岛素抵抗指数;应用 MRI 测量腹部内脏脂肪面积;比较两组患者血糖、胰岛素及胰岛素抵抗指数的差异,并分析腹型肥胖患者糖代谢相关指标与腹部脂肪面积的相关性。结果腹型肥胖组 BMI、腰围、臀围、胰岛素抵抗指数及腹部脂肪面积均高于均匀肥胖组[(28.67±4.20)、(21.80±1.97)kg/ m2,(99.75±4.07)、(79.50±10.05)cm,(104.42±7.62)、(91.86±4.49)cm,2.60±1.80、1.52±0.73,(153.06±53.23)、(71.78±25.48)cm2],差异均有统计学意义(t值分别为-7.704、-9.583、-7.618、-2.877、-7.184,P 均<0.05);腹型肥胖组0、1、2 h 血糖和胰岛素高于均匀肥胖组[(5.89±1.36)、(5.29±0.53)mmol/ L,(10.55±3.07)、(8.76±1.96)mmol/ L,(8.41±3.63)、(6.54±1.50)mmol/ L,(9.71±5.05)、(6.42±2.96)mU/ L,(83.29±64.51)、(33.00±19.82) mU/ L,(27.93±14.98)、(63.56±21.09)mU/ L],差异均有统计学意义(t 值分别为-2.098、-2.671、-2.447,-3.010、-3.784、-3.089,P 均<0.05);腹型肥胖患者腹部脂肪面积与年龄、BMI、腹围、臀围、血糖(0、1、2 h)、胰岛素(0、2 h)及胰岛素抵抗指数均呈正相关( r 值分别为0.254、0.533、0.521、0.615、0.245、0.315、0.294、0.273、0.249、0.225,P 均<0.05),校正混杂因素后,年龄(x1)、腹围(x2)及胰岛素抵抗指数(x 3)与腹部内脏脂肪面积成正相关相关(y =1.369x1+4.472x2+25.072x3-333.626)。结论与均匀肥胖相比较,腹型肥胖患者的腹部脂肪面积大小与胰岛素抵抗相关。 Objective To investigate the relationship between intra-abdominal fat area(IAFA)in male with abdominal obesity and glycometabolism related indicators. Methods Ninety-four obesity males,aged from 21 to 62 years old,were selected as our subjects. They were divided into abdominal obesity group(n = 70)and non-abdominal obesity group( n = 24). The general information of all subjects was recorded. The indexes of height,weight,waist circumference,hip circumference,body mass index(BMI)were measured. The fasting oral glucose tolerance test was performed. The levels of blood glucose(0,1,2 h)and insulin(0,1,2 h)were measured,and insulin resistance index was calculated. MRI measurement was applied to calculate the IAFA. Compared the difference between the two groups in term of the level of blood glucose,insulin and insulin resistance index,and analyzed the correlation between glycometabolism related indicators and IAFA. Results BMI,waist circumference,hip circumference,insulin resistance index and IAFA in abdominal obesity group were (28. 67 ± 4. 20)kg/ m2 ,(99. 75 ± 4. 07)cm,(104. 42 ± 7. 62)cm,2. 60 ± 1. 80,(153. 06 ± 53. 23)cm2 respectively,higher than those in non-abdominal obesity group((21. 80 ± 1. 97)kg/ m2 ,(79. 50 ± 10. 05)cm, (91. 86 ± 4. 49)cm,1. 52 ± 0. 73,(71. 78 ± 25. 48)cm2 ),and the differences were statistically significant(t= - 7. 704,- 9. 583,- 7. 618,- 2. 877,- 7. 184,P 〈 0. 05). The level of blood glucose at 0,1,2 h of patient in abdominal obesity group were(5. 89 ± 1. 36)mmol/ L,(10. 55 ± 3. 07)mmol/ L,and(8. 41 ± 3. 63) mmol/ L,higher than that in non-abdominal obesity group((5. 29 ± 0. 53)mmol/ L,(8. 76 ± 1. 96)mmol/ L, (6. 54 ± 1. 50)mmol/ L). Meanwhile,The insulin at 0,1,2 h of man in abdominal obesity group were(9. 71 ± 5. 05)mU/ L,(83. 29 ± 64. 51)mU/ L,(63. 56 ± 21. 09)mU/ L),significantly higher than those in non-abdominal obesity group((6. 42 ± 2. 96)mU/ L,(33. 00 ± 19. 82)mU/ L,(63. 56 ± 21. 09)mU/ L),and the differences were significant( t = - 2. 098,- 2. 671;- 2. 447,- 3. 010;- 3. 784,- 3. 089;P 〈 0. 05). The IAFA in abdominal obesity was positively correlated with age,BMI,waist circumference,hip circumference,blood glucose(0,1,2 h)insulin(0,2 h)and insulin resistance index(r = 0. 254,0. 533,0. 521,0. 615,0. 245,0. 315, 0. 294,0273,0. 249,0. 225,P 〈 0. 05 ). After adjustment for confounding factors,age( x1 ),abdominal circumference(x2)and insulin resistance index(x3)were related to IAFA(y = 1. 369x1 + 4. 472x2 + 25. 072x3- 333. 626). Conclusion Compared with patients with non-abdominal obesity,the IAFA of patient with abdominal obesity with abdominal fat area size is associated with insulin resistance.
出处 《中国综合临床》 2014年第7期724-726,共3页 Clinical Medicine of China
关键词 腹型肥胖 腹部脂肪面积 胰岛素抵抗 糖代谢 Abdominal obesity Abdominal fat area Insulin resistance Glucose metabolism
  • 相关文献

参考文献10

二级参考文献34

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华糖尿病杂志,2010,2(1). 被引量:550
  • 2范建高,朱军,李新建,李锐,戴菲,宋晓敏,陈兰,李锋,陈世耀.上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志,2005,13(2):83-88. 被引量:583
  • 3王金祥,胥振扬,张淑明,周建群,李晓辉,王艳平.轻中度肥胖症对非吸烟成人肺功能影响的研究[J].中国呼吸与危重监护杂志,2005,4(3):218-220. 被引量:17
  • 4余明业,郑永克.单纯性肥胖肺功能改变的研究[J].实用医学杂志,2006,22(5):547-548. 被引量:9
  • 5陆菊明.糖尿病//王吉耀.内科学.第2版.北京:人民卫生出版社,2010:1028-1059.
  • 6Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4. 4-year follow-up study. The Nord-Trcndelag Health Study ( HUNT), Norway. Am J Kidney Dis, 2003, 42:466-473.
  • 7Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol, 2004, 33 : 189-198.
  • 8Pinto-Sietsma S J, Navis G, Janssen WM, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis, 2003, gl : 733-741.
  • 9De Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol, 2007, 18: 235-243.
  • 10Chandie Shaw PK, Berger SP, Mallat M, et al. Central obesity is an independent risk factor for albuminuria in nondiabetic South Asian subjects. Diabetes Care, 2007, 30: 1840q844.

共引文献68

同被引文献56

  • 1黄晓斌.肥胖相关性高血压流行病学、病理生理及其临床管理[J].中华高血压杂志,2011,19(3):298.
  • 2Vlasova M, Purhonen AK, Jarvelin MR, et al. Role of adipokines in obesity-associated hypertension [ J]. Acta Physiol ( Oxf), 2010, 200(2) :107-127.
  • 3Yiannikouris F, Gupte M, Putnam K, et al. Adipokines and blood pressure control [J]. Curr Opin Nephrol Hypertens,2010,19(2) : 195-200.
  • 4Matsuzawa Y. Adiponectin: a key player in obesity related disorders [ J ]. Curr Pharm Des ,2010,16 ( 17 ) : 1896-1901.
  • 5王晓曦,李拥军,王梅.脂肪因子与胰岛素抵抗[J].中国综合临床,2013,29(z1):163-165.
  • 6De Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity [ J]. Diabetes, 2007,56(6) :1655-1661.
  • 7Jialal I, Devaraj S, Kaur H, et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome [ J]. J Clin Endocrinol Metab, 2013,98 (3) : E514- E517.
  • 8Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine,is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose [ J ]. Diabetes,2008,57 (4) : 801 - 808.
  • 9Greulieh S, Chen WJ, Maxhera B, et al. Cardiopreteetive properties of omentin-1 in type 2 diabetes : evidence from elinieal and in vitro studies [ J ]. PLoS One, 2013,8 ( 3 ) : e59697.
  • 10Anuurad E, Sbiwaku K, Nogi A, et al. The new BMI criteria for Asians by the regional office for the Western Pacific Region of WHO are suitable for screening overweight to prevent metabolic syndrome in elder Japanese Workers [ J ]. J Occup Health, 2003, 45 (6) :335-343.

引证文献5

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部